Celcuity Inc
CELC106.750USD
+2.470+2.37%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
4.62BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Celcuity Inc Unternehmen
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Celcuity Inc Informationen
BörsenkürzelCELC
Name des UnternehmensCelcuity Inc
IPO-datumSep 20, 2017
CEOSullivan (Brian F)
Anzahl der mitarbeiter87
WertpapierartOrdinary Share
GeschäftsjahresendeSep 20
Addresse16305 36th Ave N Ste 100
StadtMINNEAPOLIS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl55446-4285
Telefon17633920767
Websitehttps://www.celcuity.com/
BörsenkürzelCELC
IPO-datumSep 20, 2017
CEOSullivan (Brian F)
Führungskräfte von Celcuity Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.12M
+96185.00%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
89.03K
-19975.00%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+303.00%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-50.00%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Mr. David F. Dalvey
Mr. David F. Dalvey
Independent Director
Independent Director
--
--
Dr. Leo T. Furcht, M.D.
Dr. Leo T. Furcht, M.D.
Independent Director
Independent Director
--
--
Dr. Charlotte Moser, M.D., Ph.D.
Dr. Charlotte Moser, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.12M
+96185.00%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
89.03K
-19975.00%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+303.00%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-50.00%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: 6 hours ago
Aktualisiert: 6 hours ago
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Baker Bros. Advisors LP
17.11%
Sullivan (Brian F)
6.75%
Perceptive Advisors LLC
6.39%
New Enterprise Associates (NEA)
6.29%
The Vanguard Group, Inc.
4.92%
Andere
58.55%
Aktionäre
Aktionäre
Anteil
Baker Bros. Advisors LP
17.11%
Sullivan (Brian F)
6.75%
Perceptive Advisors LLC
6.39%
New Enterprise Associates (NEA)
6.29%
The Vanguard Group, Inc.
4.92%
Andere
58.55%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
34.24%
Investment Advisor
22.62%
Investment Advisor/Hedge Fund
10.53%
Individual Investor
10.28%
Venture Capital
6.86%
Private Equity
6.79%
Research Firm
5.83%
Corporation
0.76%
Pension Fund
0.18%
Andere
1.91%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
299
39.79M
87.00%
+296.61K
2025Q3
298
39.50M
98.78%
+3.79M
2025Q2
215
31.87M
95.31%
+797.76K
2025Q1
207
31.06M
92.46%
-3.93M
2024Q4
197
30.50M
91.70%
-18.57K
2024Q3
181
30.14M
86.73%
+764.96K
2024Q2
164
29.36M
68.66%
+7.16M
2024Q1
155
22.20M
60.61%
+3.55M
2023Q4
137
16.81M
74.10%
+667.49K
2023Q3
139
16.14M
75.21%
+1.37M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Baker Bros. Advisors LP
7.92M
17.11%
+170.10K
+2.20%
Sep 30, 2025
Sullivan (Brian F)
3.12M
6.75%
+96.19K
+3.18%
Sep 30, 2025
Perceptive Advisors LLC
2.96M
6.39%
+285.72K
+10.70%
Sep 30, 2025
New Enterprise Associates (NEA)
2.14M
4.63%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
2.06M
4.45%
+391.26K
+23.46%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.04M
4.42%
+174.80K
+9.35%
Sep 30, 2025
Morgan Stanley & Co. LLC
1.27M
2.74%
+743.94K
+142.39%
Sep 30, 2025
Laing (Lance G Ph.D.)
1.25M
2.7%
--
--
Sep 30, 2025
Soleus Capital Management, L.P.
1.18M
2.55%
-1.83M
-60.86%
Sep 30, 2025
Tang Capital Management, LLC
1.15M
2.49%
+1.15M
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Genomics Immunology and Healthcare ETF
5.06%
Virtus LifeSci Biotech Clinical Trials ETF
4.16%
Tema Oncology ETF
3.44%
Invesco Dorsey Wright Healthcare Momentum ETF
3.35%
ALPS Medical Breakthroughs ETF
1.34%
Invesco Dorsey Wright SmallCap Momentum ETF
0.89%
iShares Micro-Cap ETF
0.44%
VictoryShares US Small Mid Cap Value Momentum ETF
0.26%
Vanguard US Momentum Factor ETF
0.16%
State Street SPDR S&P Biotech ETF
0.15%
Mehr Anzeigen
iShares Genomics Immunology and Healthcare ETF
Anteil5.06%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil4.16%
Tema Oncology ETF
Anteil3.44%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil3.35%
ALPS Medical Breakthroughs ETF
Anteil1.34%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0.89%
iShares Micro-Cap ETF
Anteil0.44%
VictoryShares US Small Mid Cap Value Momentum ETF
Anteil0.26%
Vanguard US Momentum Factor ETF
Anteil0.16%
State Street SPDR S&P Biotech ETF
Anteil0.15%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
